Vanilloid Agonists for Desensitization of C-Fiber Sensory Afferent Neurons
Description of Invention:
Capsaicin has been proven to have therapeutic utility in the treatment of arthritis, pruritis, bladder hyperreflexia, allergic responses including rhinitis, and pain, including pain associated with cancer, peripheral neuropathies, and postherpetic neuralgia. For a number of these indications, applications have been found in veterinary as well as human medicine. Recent advances have identified capsaicin analogs with ultrapotency and with a more favorable spectrum of action, as well as subclasses of capsaicin receptors with different effects on desensitization. This invention describes a method of administering to a capsaicin-sensitive animal a therapeutically effective combination of capsaicin agonists and capsaicin-like antagonists which are more effective than the agonist alone at desensitizing a vanilloid responsive cell, and thereby improve the therapeutic index of the capsaicin agonist and overall treatment. Also described are pharmaceutical compounds which are effective in this method.
Inventors:
PM Blumberg T Biro P Acs G Acs (NCI)
Patent Status:
DHHS Reference No. E-008-1997/0 Licensing Status: This technology is no longer available for licensing.
Portfolios: Internal Medicine Central Nervous System
Central Nervous System -Therapeutics-Neurological Therapeutics-Narcotics and Analgesics Central Nervous System -Therapeutics Internal Medicine-Therapeutics
For Additional Information Please Contact: Norbert J. Pontzer PhD JD
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5502
Email: pontzern@mail.nih.gov
Fax: (301) 402-0220
